Will Glenmark’s COVID-19 drug give it a new lease of life or just a short energy boost?
The pharma major has taken a different path from peers, in launching a new drug instead of inking a licensing deal
Shruti Venkatesh - July 04, 2020
New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Tricky Transition
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
N Mahalakshmi - July 16, 2019
Growth Inhibitor
In Ankleshwar, feisty MSMEs that survived the Chinese onslaught say that the fight against red tapism is harder
Krishna Gopalan - January 25, 2019
On safer shores
Bharuch is booming on the back of great roads, ports and a powered-up electrical grid
Krishna Gopalan - July 02, 2015